AC Immune (ACIU) SA announced interim safety and tolerability data from the ABATE Phase 1b/2 trial of ACI-24.060 in individuals living with Down syndrome, DS. Targeting toxic forms of amyloid beta, ACI-24.060 is an active immunotherapy covering Abeta 1-15. The interim analysis was based on data from the first two cohorts of individuals with DS receiving low-dose and mid-dose ACI-24.060. DS subjects in the interim analysis have been treated for up to one year, with no serious adverse events related to the study drug and no case of amyloid-related imaging abnormalities, ARIA, observed in this study population.

Pick the best stocks and maximize your portfolio:

• Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!

• Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

See Insiders’ Hot Stocks on TipRanks >>

Read More on ACIU:

• AC Immune Q3 2024: Strong Progress and Financial Turnaround

• AC Immune reports interim results from Phase 2 trial of ACI-7104.056

• AC Immune’s Promising Trial Results for Parkinson’s Therapy

• AC Immune SA Reports Profitable Q3 2024 Results

• AC Immune reports Q3 EPS CHF 0.05 vs (CHF 0.18) last year